Outside the box-novel therapeutic strategies for glioblastoma

Cancer Journal

Volumn 18, Issue 1, 2012, Pages 51-58

  Mrugala, MacIej M ^a   Adair, Jennifer E ^a   Kiem, Hans Peter ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

chlorotoxin; Glioblastoma; TM 601; TTFields

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; CARMUSTINE; CHLOROTOXIN; CINTREDEKIN BESUDOTOX; CYTOTOXIN; PSEUDOMONAS EXOTOXIN; SCORPION VENOM; TOXIN; UNCLASSIFIED DRUG;

BRAIN INFECTION; BRAIN METASTASIS; CANCER SURVIVAL; CANCER THERAPY; ELECTRIC FIELD; GENE THERAPY; GLIOBLASTOMA; HISTOCHEMISTRY; HUMAN; NEURAL STEM CELL TRANSPLANTATION; NEUROLOGIC DISEASE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; UNITED STATES;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ELECTRIC STIMULATION THERAPY; GLIOBLASTOMA; HUMANS; SCORPION VENOMS;

EID: 84856699247     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318243f785     Document Type: Review

References (46)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus con-comitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activ-ity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008;17: 1225-1235.
3. Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblas-toma: a multicenter phase II trial. J Clin Oncol. 2009;27:4155-4161.
4. Rosenfeld MR, Chamberlain MC, Grossman SA, et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adju-vant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010;12:1071-1077.
5. Mc Girt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblas- tomamultiforme. J Neurosurg. 2009;110:583-588.
6. Kirson ED, Dbaly V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104:10152-10157. (Pubitemid 47175278)
7. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up ofamulticenter controlled trial. Acta Neurochir (Wien). 2006;148:269-275; discussion 275. (Pubitemid 43341024)
8. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrentmalignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007;25:837-844. (Pubitemid 350002884)
9. Vogelbaum MA, Sampson JH, Kunwar S, et al. Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study offinal safety results. Neurosurgery. 2007;61:1031-1037; discussion 1037-1038. (Pubitemid 350306946)
10. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12:871-881.
11. Yamaizumi M, Mekada E, Uchida T, et al. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15: 245-250. (Pubitemid 9027527)
12. Gatter KC, Brown G, Trowbridge IS, et al. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol. 1983;36:539-545. (Pubitemid 13089724)
13. Lao BJ, Tsai WL, Mashayekhi F, et al. Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J Control Release. 2007;117:403-412. (Pubitemid 46216586)
14. Debinski W. Molecular targeting with recombinant cytotoxins for the treatment of brain tumors. Drug Dev Res. 2008;69:407-414.
15. Candolfi M, Kroeger KM, Xiong W, et al. Targeted toxins for glio-blastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem. [published online ahead ofprint June 27, 2011].
16. Oh S, Ohlfest JR, Todhunter DA, et al. Intracranial elimination ofhuman-glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery J Neurooncol. 2009; 95:331-342.
17. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracra-nial gliomas. Proc Natl Acad Sci US A. 2000;97:12846-12851.
18. Lee SJ, Kim Y, Jo MY, et al. Combined treatment oftumor-tropic human neural stem cells containing the CD suicide gene effectively targets brain tumors provoking amildimmuneresponse. Oncol Rep. 2011;25:63-68
19. A pilot feasibility study oforal 5-fluorocytosine and genetically-modified neural stem cells expressing E. coli cytosine deaminase for treatment of recurrent high grade gliomas. Available at: www.clinicaltrials. gov.
20. Ullrich N, Gillespie GY, Sontheimer H. Human astrocytoma cells ex-press a unique chloride current. Neuroreport. 1995;7:343-347. (Pubitemid 26078186)
21. Ullrich N, Gillespie GY, Sontheimer H. Human astrocytoma cells ex-press a unique chloride current. Neuroreport. 1996;7:1020-1024. (Pubitemid 26194473)
22. Ullrich N, Bordey A, Gillespie GY, et al. Expression ofvoltage-activated chloride currents in acute slices of human gliomas. Neuroscience. 1998; 83:1161-1173. (Pubitemid 28114208)
23. Soroceanu L, Gillespie Y, Khazaeli MB, et al. Use of chlorotoxin for targetingofprimarybraintumors. Cancer Res. 1998;58:4871-4879.
24. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia. 2002;39:162-173. (Pubitemid 34817056)
25. Jacoby DB, Dyskin E, Yalcin M, et al. Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res. 2010;30:39-46.
26. Mamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recur-rent high-grade glioma. J Clin Oncol. 2006;24:3644-3650. (Pubitemid 46630539)
27. Hockaday DC, Shen S, Fiveash J, et al. Imaging glioma extent with I-TM-601. J Nucl Med. 2005;46:580-586.
28. Fiveash JBNL, Badie B, Mamelak AN, et al. A randomized phase II study of intracavitary 131-I-TM-601 in the treatment ofrecurrent ma-lignant glioma. Presented at the Society for Neuro-Oncology Annual Meeting; 2009; New Orleans, LA.
29. Akella NSNL, Rosenfeld SS, Chamberlain MC, et al. A phase I evalu-ation of intravenous TM-601 in recurrent glioblastoma: use pfperfu-sion MRI to monitor anti-angiogenic effects. Presented at the American Society of Clinical Oncology Annual Meeting; 2009; Orlando, FL.
30. Veiseh M, Gabikian P, Bahrami SB, et al. Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 2007;67:6882-6888. (Pubitemid 47105535)
31. Stummer W, Novotny A, Stepp H, et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. JNeurosurg. 2000;93:1003-1013. (Pubitemid 32800611)
32. Pichlmeier U, Bink A, Schackert G, et al. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol. 2008;10:1025-1034.
33. Sun C, Veiseh O, Gunn J, et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small. 2008;4: 372-379. (Pubitemid 351421268)
34. Sun C, Fang C, Stephen Z, et al. Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparti-cles. Nanomedicine (Lond). 2008;3:495-505.
35. Veiseh O, Gunn JW, Kievit FM, et al. Inhibition of tumor-cell inva-sion with chlorotoxin-bound superparamagnetic nanoparticles. Small. 2009;5:256-264.
36. Bassett CA. Electrical stimulation ofrepair ofbone. JBone Joint Surg Am. 1987;69:1110-1111.
37. Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64: 3288-3295. (Pubitemid 38581435)
38. Jordan MA, Thrower D, Wilson L. Effects ofvinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci. 1992;102(Pt 3):401-416.
39. Rowinsky EK, Donehower RC. Paclitaxel (taxol). NEngl JMed. 1995; 332:1004-1014.
40. Endlich B, Radford IR, Forrester HB, et al. Computerized video time-lapse microscopy studies of ionizing radiation-induced rapid-interphase and mitosis-related apoptosis in lymphoid cells. Radiat Res. 2000;153: 36-48. (Pubitemid 30117082)
41. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578. (Pubitemid 29368260)
42. Food and Drug Administration Neurological Devices Panel. Novo TTF-100A System. Silver Spring, MD: FDA; 2011:1-305.
43. Stupp RKA, Engelhard H, Heidecke V, et al. A prospective, randomized, open-label, phase III clinical trial of Novo TTF-100Aversus best standard of care chemotherapy in patients with recurrent glioblastoma. J Clin Oncol. 2010;28[18 suppl]:LBA2007.
44. Iwamoto FM, Abrey LE, Beal K, et al. Patterns ofrelapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73: 1200-1206.
45. Kirson ED, Schneiderman RS, Dbaly V, et al. Chemotherapeutic treat-ment efficacy and sensitivity are increased by adjuvant alternating elec-tric fields (TTFields). BMCMed Phys. 2009;9:1
46. Effect of Novo TTF-100A togetherwith temozolomide in newly diagnosed glioblastoma multiforme (GBM). Available at: www.clinicaltrials.gov.